BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 30716392)

  • 1. Denervation-induced skeletal muscle fibrosis is mediated by CTGF/CCN2 independently of TGF-β.
    Rebolledo DL; González D; Faundez-Contreras J; Contreras O; Vio CP; Murphy-Ullrich JE; Lipson KE; Brandan E
    Matrix Biol; 2019 Sep; 82():20-37. PubMed ID: 30716392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of hypoxia in skeletal muscle fibrosis: Synergism between hypoxia and TGF-β signaling upregulates CCN2/CTGF expression specifically in muscle fibers.
    Valle-Tenney R; Rebolledo DL; Lipson KE; Brandan E
    Matrix Biol; 2020 May; 87():48-65. PubMed ID: 31669521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALS skeletal muscle shows enhanced TGF-β signaling, fibrosis and induction of fibro/adipogenic progenitor markers.
    Gonzalez D; Contreras O; Rebolledo DL; Espinoza JP; van Zundert B; Brandan E
    PLoS One; 2017; 12(5):e0177649. PubMed ID: 28520806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.
    Morales MG; Gutierrez J; Cabello-Verrugio C; Cabrera D; Lipson KE; Goldschmeding R; Brandan E
    Hum Mol Genet; 2013 Dec; 22(24):4938-51. PubMed ID: 23904456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of CTGF/CCN2 in response to LPA is stimulated by fibrotic extracellular matrix via the integrin/FAK axis.
    Riquelme-Guzmán C; Contreras O; Brandan E
    Am J Physiol Cell Physiol; 2018 Apr; 314(4):C415-C427. PubMed ID: 29351412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTGF/CCN2 exerts profibrotic action in myoblasts via the up-regulation of sphingosine kinase-1/S1P3 signaling axis: Implications in the action mechanism of TGFβ.
    Bruno G; Cencetti F; Pertici I; Japtok L; Bernacchioni C; Donati C; Bruni P
    Biochim Biophys Acta; 2015 Feb; 1851(2):194-202. PubMed ID: 25457224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2).
    Morales MG; Cabrera D; Céspedes C; Vio CP; Vazquez Y; Brandan E; Cabello-Verrugio C
    Cell Tissue Res; 2013 Jul; 353(1):173-87. PubMed ID: 23673415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SMAD3 and SP1/SP3 Transcription Factors Collaborate to Regulate Connective Tissue Growth Factor Gene Expression in Myoblasts in Response to Transforming Growth Factor β.
    Córdova G; Rochard A; Riquelme-Guzmán C; Cofré C; Scherman D; Bigey P; Brandan E
    J Cell Biochem; 2015 Sep; 116(9):1880-7. PubMed ID: 25727481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CTGF/CCN2 from Skeletal Muscle to Nervous System: Impact on Neurodegenerative Diseases.
    Gonzalez D; Brandan E
    Mol Neurobiol; 2019 Aug; 56(8):5911-5916. PubMed ID: 30689195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Driving fibrosis in neuromuscular diseases: Role and regulation of Connective tissue growth factor (CCN2/CTGF).
    Rebolledo DL; Lipson KE; Brandan E
    Matrix Biol Plus; 2021 Aug; 11():100059. PubMed ID: 34435178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Connective tissue growth factor expression after angiotensin II exposure is dependent on transforming growth factor-β signaling via the canonical Smad-dependent pathway in hypertensive induced myocardial fibrosis.
    Wong CKS; Falkenham A; Myers T; Légaré JF
    J Renin Angiotensin Aldosterone Syst; 2018; 19(1):1470320318759358. PubMed ID: 29575960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal muscle cells express the profibrotic cytokine connective tissue growth factor (CTGF/CCN2), which induces their dedifferentiation.
    Vial C; Zúñiga LM; Cabello-Verrugio C; Cañón P; Fadic R; Brandan E
    J Cell Physiol; 2008 May; 215(2):410-21. PubMed ID: 18064627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease.
    Riser BL; Najmabadi F; Perbal B; Peterson DR; Rambow JA; Riser ML; Sukowski E; Yeger H; Riser SC
    Am J Pathol; 2009 May; 174(5):1725-34. PubMed ID: 19359517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inhibition of CTGF/CCN2 activity improves muscle and locomotor function in a murine ALS model.
    Gonzalez D; Rebolledo DL; Correa LM; Court FA; Cerpa W; Lipson KE; van Zundert B; Brandan E
    Hum Mol Genet; 2018 Aug; 27(16):2913-2926. PubMed ID: 29860398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II-induced pro-fibrotic effects require p38MAPK activity and transforming growth factor beta 1 expression in skeletal muscle cells.
    Morales MG; Vazquez Y; Acuña MJ; Rivera JC; Simon F; Salas JD; Alvarez Ruf J; Brandan E; Cabello-Verrugio C
    Int J Biochem Cell Biol; 2012 Nov; 44(11):1993-2002. PubMed ID: 22964022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCN2, connective tissue growth factor, stimulates collagen deposition by gingival fibroblasts via module 3 and alpha6- and beta1 integrins.
    Heng EC; Huang Y; Black SA; Trackman PC
    J Cell Biochem; 2006 May; 98(2):409-20. PubMed ID: 16440322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model.
    Chujo S; Shirasaki F; Kawara S; Inagaki Y; Kinbara T; Inaoki M; Takigawa M; Takehara K
    J Cell Physiol; 2005 May; 203(2):447-56. PubMed ID: 15605379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taurocholate Induces Connective Tissue Growth Factor Expression in Hepatocytes Through ERK-YAP Signaling.
    Yu B; Jin GN; Ma M; Liang HF; Zhang BX; Chen XP; Ding ZY
    Cell Physiol Biochem; 2018; 50(5):1711-1725. PubMed ID: 30384360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking CTGF/CCN2 reduces established skeletal muscle fibrosis in a rat model of overuse injury.
    Barbe MF; Hilliard BA; Amin M; Harris MY; Hobson LJ; Cruz GE; Popoff SN
    FASEB J; 2020 May; 34(5):6554-6569. PubMed ID: 32227398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic manipulation of CCN2/CTGF unveils cell-specific ECM-remodeling effects in injured skeletal muscle.
    Petrosino JM; Leask A; Accornero F
    FASEB J; 2019 Feb; 33(2):2047-2057. PubMed ID: 30216109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.